Thabo Dlamini, a computational biologist hunched over glowing screens in a lab at the University of Cape Town, didn’t set out to unmask a traitor—but that’s exactly what he and his team did. Deep within the cellular architecture of the human body, a protein called Mucin-1 (MUC1), once a loyal guardian of epithelial tissues like those in the breast, colon, and lungs, turns rogue in cancer. Now, Dlamini’s team has decoded how this betrayal unfolds at the molecular level, revealing a precise mechanism that could unlock new vaccines and therapies.
In healthy cells, MUC1 stands sentinel on the cell surface, its long, complex sugar chains acting as both armor and communicator—shielding against pathogens while signaling immune defenses. But in cancer, this protective shield undergoes a malignant makeover. The sugar chains are truncated, forming aberrant structures like the Tn and sialyl-Tn (sTn) antigens, which not only cloak tumor cells from immune detection but actively drive malignancy. Because MUC1 is overexpressed in more than 80% of human carcinomas, the U.S. National Cancer Institute has ranked it the top target for cancer immunotherapy.
The breakthrough came when Dlamini’s team at the Scientific Computing Research Unit recreated this transformation outside the cell. Using a novel synthetic biology approach in a test-tube model, they mapped how the cellular “assembly line” for sugar attachment—glycosylation—goes awry. Normally, enzymes that build sugar chains operate in the Golgi apparatus. But in cancer, these enzymes relocate to the endoplasmic reticulum, where unchecked, they hijack MUC1 at specific sites. Through quantum-level simulations, the team pinpointed the T13 site on the MUC1 protein as the prime hotspot for this cancerous sugar attachment, where sTn antigen levels skyrocket.
Published in Nature Communications (2026, DOI: 10.1038/s41467-026-72151-y), this South African-led research provides the first detailed map of how cancer reprograms MUC1’s glycosylation to evade immunity. The discovery isn’t just academic—it lays the foundation for designing vaccines that train the immune system to recognize the altered sugar signatures, or therapeutics that block the enzyme relocation altogether.
For a disease that claims nearly 10 million lives a year globally, this molecular intelligence could be a turning point. As research teams worldwide build on this work, the path to intercepting cancer’s stealth strategy is no longer theoretical. It’s now written in the language of sugars and proteins—and for the first time, we can read it.